The US Food and Drug Administration (FDA) has granted approval to the MediBeacon Transdermal GFR (TGFR) system for evaluating kidney function in individuals with normal or impaired renal function. The ...
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...
The FDA has approved MediBeacon®'s TGFR system for noninvasive kidney function assessment, targeting both normal and impaired renal patients. INNOVATE Corp. announced the FDA approval of the ...
MediBeacon has received the CE Mark certification under the European Union (EU) Medical Device Regulation (MDR) for its transdermal glomerular filtration rate (TGFR) monitor and reusable sensor. The ...
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The Clinical Kidney Journal in February ...
ST. LOUIS, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced ...
MediBeacon® TGFR™ System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers begins in early 2026 ST.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results